Neurogene Inc: chief scientific officer Cobb sells $141k in stock
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil resumes climb after previous session’s respite as Iran supply fears persist Wall Street extends this week’s rebound a day ahead of Fed interest rate decision Up 31%+, this AI-picked energy infrastructure play is a Middle East conflict win Oil inventories seen falling to record lows in April amid Hormuz disruptions 55% Off - FLASH SALE (South Africa Philippines Nigeria) 55% Off - FLASH SALE Neurogene Inc: chief scientific officer Cobb sells $141k in stock By Insider Trading Published 03/17/2026, 06:13 PM Neurogene Inc: chief scientific officer Cobb sells $141k in stock 0 NGNE -2.27% Neurogene Inc. (NASDAQ:NGNE) Chief Scientific Officer Stuart Cobb sold 6,797 shares of common stock on March 13, 2026, for approximately $141,445. The sales occurred in multiple transactions with prices ranging from $19.94 to $22.16. The transactions came as the stock trades at $21.08, down 8.6% over the past week in what has been characteristically volatile price action for the biotech company. According to a Form 4 filing with the Securities and Exchange Commission, the transactions were executed under a pre-arranged 10b5-1 trading plan adopted on February 6, 2025. Following the reported transactions, Cobb directly owns 30,497 shares of Neurogene Inc. common stock. InvestingPro subscribers have access to 11 additional ProTips for NGNE, along with comprehensive analysis ahead of the company’s earnings report scheduled for March 19. In other recent news, Neurogene Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its investigational gene therapy, NGN-401, for Rett syndrome. This designation was based on interim efficacy and safety data from the Phase 1/2 trial, highlighting functional improvements in various Rett syndrome domains. Additionally, Neurogene has dosed multiple participants in its Embolden registrational trial for NGN-401, with the company planning to complete ...
Read full article at source